FRONTIER SCIENCE | PUBLICATIONS

The HERA Trial: Adjuvant trastuzumab therapy reduces the risk of relapse across subgroups

OVERVIEW

An assessment of the magnitude of the clinical benefits of trastuzumab for subpopulations defined by nodal and steroid hormone receptor status using data from the Herceptin Adjuvant (HERA) study.

TITLE OF PUBLICATION

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

AUTHORS

Untch, M., Gelber, R.D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B. and de Azambuja, E.

PUBLICATION REFERENCE

Annals of Oncology | Volume 19 | Issue 6 | Pages 1090-1096 | June 2008

READ FULL PUBLICATION

MORE PUBLICATIONS FROM FRONTIER SCIENCE SCOTLAND

APHINITY | European Journal of Cancer (EJC)

APHINITY | European Journal of Cancer (EJC)

Mar 18, 2022

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

read more
APHINITY | AACR Cancer Research

APHINITY | AACR Cancer Research

Feb 15, 2022

Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.

read more
The APHINITY Trial: Results of the Primary Analysis

The APHINITY Trial: Results of the Primary Analysis

Jul 13, 2017

An article published in the New England Journal of Medicine (NEJM) reports that pertuzumab, when added to chemotherapy and trastuzumab, significantly improved the rates of invasive-disease–free survival among patients with HER2-positive early breast cancer.

read more
The ALTTO Trial: Results of the Primary Analysis

The ALTTO Trial: Results of the Primary Analysis

Apr 1, 2016

An article in the JCO reports that adjuvant treatment that includes lapatinib did not significantly improve Disease-Free Survival compared with trastuzmab alone and added toxicity. One year of adjuvant trastuzumab remains standard of care.

read more